SCHEMBL274137

SCHEMBL274137

Cc1cccc(/C=N/NC(=O)c2cc(Br)ccc2NC(=O)c2ccccn2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
NPC1 O15118 12/20 0.54
GAA P10253 6/20 0.54
MAPT P10636 3/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
HPGD P15428 1/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
OPRK1 P41145 2/20 0.51
MGAM O43451 1/20 0.50
SI P14410 1/20 0.50
MGAM2 Q2M2H8 1/20 0.50
BACE1 P56817 1/20 0.48
PKM P14618 3/20 0.47
POLB P06746 2/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268992 1.00 RAB9A (0.57) RAB9ASMN1; SMN2NPC1GAAMAPT
SCHEMBL267031 0.91 NPC1 (0.55) RAB9ASMN1; SMN2NPC1GAAMAPT
SCHEMBL273957 0.91 NPC1 (0.55) RAB9ASMN1; SMN2NPC1GAAMAPT
Hydrochloric Acid SCHEMBL265826 0.90 NPC1 (0.54) RAB9ASMN1; SMN2NPC1GAAMAPT
SCHEMBL266553 0.89 NPC1 (0.53) RAB9ASMN1; SMN2NPC1GAAMAPT
SCHEMBL273716 0.89 NPC1 (0.53) RAB9ASMN1; SMN2NPC1GAAMAPT
SCHEMBL268120 0.88 MEN1 (0.51) RAB9ASMN1; SMN2NPC1GAAMAPT
SCHEMBL273686 0.88 MEN1 (0.51) RAB9ASMN1; SMN2NPC1GAAMAPT
SCHEMBL269535 0.88 MEN1 (0.51) RAB9ASMN1; SMN2NPC1GAAMAPT
SCHEMBL274295 0.88 MEN1 (0.51) RAB9ASMN1; SMN2NPC1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 RAB9A 1362/4885SMN1; SMN2 4253/4885NPC1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.